Does the vax deal matter?, page-5

Hi cjlt

PROFESSOR IAN FRAZER'S vaccine platform has huge potential, its based on proteins which are amino acids like E16 and E17 that clear the path to the nerve endings where the cancer is hidden.

Now if a company in 2013 was valued at 200M dollars on the potential HPV vaccine, then how about imuno-oncology head and neck cancer?

This is the HOTTEST field to be in at this moment in time. Multinationals are accumulating Bio companies in the US and Australia.

The platform was created to enhance vaccines, eg; If other companies have a vaccine that works at 50% and ADMEDUS adds the protein and improves it by even 10% then ALL companies will be heading to ADMEDUS for proteins. Now one man's rubbish is another man's treasure. Don't through the baby out with the bath water. The company is worth a lot more than what SH's realise.

The best outcome for ADMEDUS would be to retain a controlling interest of 51% in the AI company. This would be ideal before floating the two companies on the NASDAQ.

PS: So what I'm saying is, hold your shares in both companies.














.